ABSTRACT Enhanced atrioventricular nodal conduction (EAVC) comprises a portion of the spectrum of atrioventricular node electrophysiology in which physiologic slowing of atrioventricular conduction is diminished. To evaluate the basis of EAVC in humans, we compared the effect of pharmacologic autonomic blockade on electrophysiologic characteristics of atrioventricular nodal conduction and refractoriness in 10 patients with EAVC and 12 patients without EAVC (non-EAVC). The effects of autonomic blockade (0.2 mg/kg iv propranolol and 0.04 mg/kg iv atropine) on sinus cycle length and atrial refractory period were similar in both EAVC and non-EAVC patients. After autonomic blockade, minimum atrial paced cycle length with 1:1 atrioventricular conduction lengthened in EAVC patients (control, 268 + 25 msec; blockade, 307 ± 34 msec; p < .01), but remained unchanged in non-EAVC patients (control, 392 + 69 msec; blockade, 382 + 49 msec; p NS).
Similarly, atrioventricular nodal functional refractory periods tended to lengthen in EAVC patients, while remaining unchanged or shortening in non-EAVC patients. Furthermore, although autonomic blockade reduced differences between EAVC and non-EAVC patients, both minimum cycle length with 1:1 atrioventricular conduction and atrioventricular functional refractory period remained shorter in EAVC than in non-EAVC patients (p < .02). Thus, baseline differences in autonomic atrioventricular nodal control differ in EAVC and non-EAVC patients, but do not fully account for differences in atrioventricular nodal electrophysiologic properties in these patients. Consequently, underlying structural functional factors may play an important role in determining the range of atrioventricular nodal electrophysiologic characteristics in man. Circulation 69, No. 6, 1088-1095, 1984. MULTIPLE FACTORS determine the capacity of the atrioventricular node to induce physiologic slowing of conduction of atrial impulses in humans. Previous studies have suggested that interactions among autonomic neural influences,1 atrial excitation wavefronts,5. 6 atrioventricular nodal size and morphology,7-9 and the presence of partial or complete bypass of atrioventricular nodal tissue by accessory connections9" account for the range of normal atrioventricular nodal electrophysiologic properties. 12 13 In some individuals atrioventricular conduction is characterized by an apparently diminished capacity of the atrioventricular node to induce physiologic conduction delay; these patients have been defined as having enhanced atrioventricular nodal conduction (EAVC). 12. 14 Although atrioventricular nodal function in such patients may comprise a portion of the normal spectrum of its electrophysiologic function,'2 15 individuals with EAVC are susceptible to development of very rapid heart rates during certain supraventricular tachyarrhythmias. 2' 14 Furthermore, alteration of the usual delay-producing capability of the atrioventricular junction adversely influences effectiveness of antiarrhythmic therapy of these arrhythmias. '5 This study was designed to determine whether extrinsic neural influences are primarily responsible for occurrence of diminished capacity of the atrioventricular junction to induce physiologic slowing of conduction in some patients. To this end, patients without clinically significant heart disease were divided into two subgroups based on static and dynamic measures of atrioventricu-PATHOPHYSIOLOGY AND NATURAL HISTORY-ELECTROPHY'SIOLOGY lar nodal function, and electrophysiologic characteristics of atrioventricular nodal conduction and refractoriness after pharmacologic autonomic blockade were reassessed.
Methods
Patient selection. Twenty-two patients (1 1 women, 1 1 men; age range 13 to 66 years) were included in this study based on the following criteria: (1) absence of cardiac disease, as evidenced by normal findings on physical examination, echocardiogram, and chest x-ray (except in patient 2, as discussed below), (2) normal PR interval (0.13 to 0.20 sec) during sinus rhythm, as documented on a 12-lead electrocardiogram, (3) absence of ventricular preexcitation (i.e., accessory atrioventricular, nodoventricular, or fasciculoventricular connections capable of conduction in the antegrade [atrioventriculari direction), as documented by both absence of a delta wave on 12-lead electrocardiogram and by findings during detailed electrophysiologic study, (4) withdrawal of all cardioactive medications for at least three drug half-lives before evaluation of atrioventricular conduction properties, (5) absence of a medical history or clinical findings contraindicating administration of atropine and propranolol (e.g., obstructive pulmonary disease, glaucoma, or urinary tract obstruction).
Indications for electrophysiologic study were recurrent supraventricular tachycardia in 10 patients, ventricular tachyarrhythmias in seven patients (asymptomatic in five of seven, symptomatic in two of seven, dizziness in four patients), and late (2 months) postoperative evaluation of atrioventricular conduction in one patient who had undergone successful surgical ablation of an accessory atrioventricular connection. Only one patient (patient 2) was suspected of having clinically significant underlying heart disease (cardiomyopathy) at time of study, but apart from minimal enlargement of the left ventricle on the chest xray, no other abnormalities were apparent and there was no evidence of congestive heart failure. No patient had been treated with cardiac glycosides within 1 month of electrophysiologic study. All patients (and patients' parents when required) gave written informed consent before initiation of these studies.
Clinical electrophysiologic procedure. The electrophysiologic techniques used in this laboratory have been described previously.'2' 14 In brief, after percutaneous cannulation of the right femoral vein of each patient, four standard No. 6F multipolar electrode catheters (1 cm interelectrode spacing) were positioned under fluoroscopic control at the high lateral border of the right atrium, across the tricuspid valve (to record His bundle electrograms), at the apex of the right ventricle, and within the coronary sinus. Local anesthesia with subcutaneous lidocaine, in minimum effective doses, was used during catheter insertion. In addition, diazepam (2.5 to S mg iv) was administered as necessary to provide light sedation. The range of total cumulative doses of diazepam used in this study was S to 20 mg.
Electrical stimulation of the heart was performed with a custom-designed constant-current pulse generator with optically isolated outputs. Pulse amplitude was set at twice diastolic threshold with a pulse width of 2 msec. Recordings were obtained at paper speed of 100 mm/sec with an Electronics for Medicine VR-12 recorder. All electrical equipment was carefully grounded.
Drug studies. The following protocol was used to assess atrioventricular nodal conduction and refractory characteristics. As expected by definition of the patient subgroups, the control minimum cycle length with 1:1 atrioventricular conduction was shorter (p < .001) in EAVC patients than in non-EAVC patients (table 3) . After administration of propranolol-atropine this difference in minimum cycle length with 1:1 atrioventricular conduction between EAVC and non-EAVC patient groups diminished, but remained statistically significant (p < .02). Furthermore, four of 10 EAVC patients (patients 2,3,6, and 9) continued to exhibit 1:1 atrioventricular conduction at cycle lengths of 300 msec or less after autonomic blockade. On the other hand, only one non-EAVC patient (patient 22) exhibited 1:1 atrioventricular conduction to a cycle length of 300 msec, a finding that had also been observed before propranolol-atropine in that individual (table 3) . Figure 2 illustrates the maximum AH intervals with <300  380  360  13  340  <240  290  385  380  340  <300  <270  340  330  14  380  300  260  355  355  360  280  280  350  355   15  400  300  <275  380  380  380  300  310  385  410  16  360  <290  <300  385  350  380  <275  <300  370  360  17  550  460  550   -500  _  18  340  <250  <285  344  330  360  260  290  365  350  19  440  380  460   -400  <245  305  420  20  420  340  410  400  315  395  21  450  430  460  420  320  390  22  300  240  <220  380  360  300  <220  <225  380  350  Mean  392  320  279  410  361  382   280   281  376  359  +SD  +69  +71  +30  +57  -+-22  ±49  +31  +28  +22 erties of the node in the control state. Second, although pharmacologic autonomic blockade diminishes observed differences among patients with respect to the capacity of the atrioventricular node to induce physiologic conduction delay compared with the control state, significant differences persist (figures 1 and 4), suggesting that neural control alone does not fully account for the wide range of observed electrophysiologic properties.
Neural influence on atrioventricular nodal function. In both animal3 and human4 studies, the combined effect of parasympathetic and sympathetic influences on electrophysiologic properties of the atrioventricular node appears to be balanced. In animals, electrical stimulation of vagal and sympathetic nerves has been used to assess the relative influence of the two limbs of the nervous system in atrioventricular nodal conduction, as measured by changes in the PR interval on the surface electrocardiogram. In the absence of either vagal or sympathetic stimulation, a condition analogous to combined pharmacologic autonomic blockade, the PR interval was unchanged from control value.3
Thus, from these studies it may be concluded that atrioventricular nodal conduction in the control state is influenced to equivalent but opposite degrees by parasympathetic and sympathetic innervation. A similar conclusion was derived in a recent study in humans in which the minimum cycle length with 1:1 atrioventricular conduction did not differ significantly from the control value after pharmacologic autonomic blockade.4
The extent to which baseline atrioventricular nodal electrophysiologic characteristics influence atrioventricular node response after autonomic blockade has not been examined previously. Our findings indicate that patients exhibiting reduced atrioventricular nodal conduction delay in the control state (EAVC patients) show more atrioventricular nodal delay-producing capacity after blockade than do non-EAVC patients. Conversely, patients manifesting a greater degree of atrioventricular nodal conduction-delay capability in the control state (non-EAVC) appear to exhibit less delay-producing capability after receiving propranolol-atropine. In this context, increased delay-producing capability is best described as the capacity of the atrioventricular node to prolong atrioventricular conduction time (i.e., the AH interval) to a maximum value over a shorter range of pacing cycle lengths. The converse implies diminished delay-producing capacity. The maximum achievable value of the AH interval, on the other hand, appears to be largely independent of the baseline electrophysiologic characteristics of the atrioventricular node. electrophysiologic characteristics is due primarily to differences in baseline neural influence. Thus, individuals manifesting parasympathetic predominance would be expected to manifest more rapid atrioventricular nodal conduction after autonomic blockade, whereas the reverse would be expected in patients exhibiting baseline sympathetic predominance. Further, unlike in the sinus node, where parasympathetic predominance is common, it would be expected that electrophysiologic changes induced by autonomic blockade within the atrioventricular node would be balanced in a large patient group given the relatively equal distribution of sympathetic and parasympathetic autonomic influences on atrioventricular nodal function.3 4 However, our findings also indicate that differences in atrioventricular nodal electrophysiologic properties in the control state persist after autonomic blockade. The latter observation argues against neural influences being the sole determinants of baseline atrioventricular nodal functional differences, and supports the view that underlying atrioventricular nodal structural-functional differences may account in part for the wide range of conduction delay-producing capacities. The nature of these differences, and whether they are of developmental or acquired origin, has not yet been ascertained. 1:3.3. This ratio approximates neither the ratio of body weights nor the ratio of heart weights in these species, suggesting that factors that were not accounted for in this analysis (e.g., neural influences, activation wave fronts and electrotonic interactions, cellular electrophysiologic properties, and histologic differences) are of major importance in determining characteristics of conduction and refractoriness within the atrioventricular node.
Clinical implications. It has previously been demonstrated that static and dynamic measures of atrioventricular nodal function in man are normally distributed. 2 Thus, patients in whom the atrioventricular node exhibits diminished delay-producing capacity represent only a portion of the spectrum of atrioventricular nodal physiology and not an isolated subset of individuals. Nonetheless, previous studies suggest that patients with certain supraventricular tachycardias and in whom diminished atrioventricular nodal conduction delay is present are susceptible to development of extremely rapid heart rates. 14Furthermore, the medical management of arrhythmias in such patients may be very difficult. 5 Therefore, an understanding of the basis for the occurrence of diminished delay-producing capability is potentially clinically important.
Our findings suggest that sympathetic neural influences predominate within the atrioventricular node in EAVC patients. Therefore, it may be expected that f3-adrenergic blockers would be more effective in such patients than would drugs designed to enhance parasympathetic influences (e.g., cardiac glycosides). On the other hand, since our findings after autonomic blockade indicate that intrinsic atrioventricular nodal conduction in EAVC patients continues to be relatively rapid (compared with non-EAVC patients), drugs that slow conduction by a direct membrane effect (e.g., "'slow inward current" blocking drugs, type 1 antiar-rhythmic drugs) may be more beneficial than either digitalis or /3-adrenergic blockers for treatment of supraventricular tachyarrhythmias in these individuals. 
